Targeting CD8+ T-cell tolerance for cancer immunotherapy.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 4215555)

Published in Immunotherapy on January 01, 2014


Stephanie R Jackson1, Jinyun Yuan, Ryan M Teague

Author Affiliations

1: Saint Louis University School of Medicine, Department of Molecular Microbiology & Immunology, 1100 South Grand Blvd, St Louis, MO 63104, USA.

Associated clinical trials:

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma | NCT00094653

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001) | NCT01295827

Multiple Ascending Dose (MDX1105-01) (Anti-PDL1) | NCT00729664

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) | NCT01354431

A Phase 1 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | NCT01375842

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | NCT01844505

Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy | NCT01029366

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | NCT01024231

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | NCT00466531

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | NCT01629758

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) | NCT01866319

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | NCT01928394

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 | NCT01176461

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer (GBM) | NCT00045968

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | NCT01307267

CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM) | NCT01109095

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | NCT01103635

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (CRETI-NH) | NCT00586391

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer | NCT01303705

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT) | NCT01582672

A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | NCT01021059

Phase II, 2nd Line Melanoma - RAND Monotherapy | NCT00612664

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | NCT01975831

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab | NCT01515189

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (CheckMate 069) | NCT01927419

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | NCT01471210

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission | NCT01096602

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer | NCT01352884

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" | NCT01903993

Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy (HERCREEM) | NCT00889954

A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) | NCT02060188

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | NCT01522820

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (OX40 Breast) | NCT01862900

A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer | NCT01804465

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation | NCT01067287

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN (GRAIN) | NCT01822652

PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | NCT01441765

Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma | NCT01952769

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | NCT00670748

Study of Gene Modified Immune Cells in Patients With Advanced Melanoma (F5) | NCT00910650

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer | NCT01832870

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (D4190C00006) | NCT02000947

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma | NCT00621452

Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma | NCT01689974

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer | NCT01417000

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting (ECLIPSE) | NCT02004262

Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors | NCT00607048

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma | NCT01435369

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer | NCT01644968

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | NCT01735604

Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) | NCT01385423

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | NCT02085070

Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | NCT02089685

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | NCT01727076

Continuous Infusion of rhIL-15 for Adults With Advanced Cancer | NCT01572493

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma | NCT00471887

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | NCT01815749

Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas | NCT01723306

iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma/VEGAS | NCT01953900

Redirected Auto T Cells for Advanced Myeloma | NCT01352286

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | NCT01875601

Study of BMS-663513 in Patients With Advanced Cancer | NCT00309023

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | NCT00338377

CD19 Redirected Autologous T Cells | NCT01747486

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | NCT01701674

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer | NCT02013219

Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer (REALISTIC:) | NCT01598792

Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma | NCT01585194

Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | NCT01266460

Gemcitabine and CT-011 for Resected Pancreatic Cancer | NCT01313416

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma | NCT01489059

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | NCT01885897

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | NCT01967823

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies | NCT01697527

A Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "BIRCH" | NCT02031458

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | NCT01369888

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes | NCT01273181

Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma | NCT01803152

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma | NCT01649024

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ (ADXS11-001) | NCT01116245

Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia | NCT02030847

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) (CARPASCIO) | NCT02050347

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | NCT01312376

Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12 | NCT00622401

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer | NCT00683241

A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | NCT01697800

Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma | NCT02051257

Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | NCT01689870

A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment | NCT01561911

Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma | NCT01675765

CT Antigen TCR-Engineered T Cells for Myeloma | NCT01892293

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod | NCT00799110

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | NCT00706992

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321) | NCT01308294

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | NCT01946789

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes | NCT00509496

Safety and Efficacy Study of DCVax-Direct in Solid Tumors | NCT01882946

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT01834248

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma (LIFT) | NCT01275209

Articles cited by this

(truncated to the top 100)

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Dendritic cells and the control of immunity. Nature (1998) 56.54

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med (2000) 16.09

Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 15.73

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63

Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med (2001) 9.70

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60

TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43

Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55

Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science (2006) 6.38

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol (2006) 6.22

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09

Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med (1994) 5.60

New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med (1982) 5.47

The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol (2009) 5.44

Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30

Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23

Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol (2003) 5.07

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med (2004) 5.07

Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med (2000) 5.07

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (2011) 4.96

Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol (2008) 4.90

Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med (1955) 4.89

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80

Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol (2003) 4.66

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60

Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med (2000) 4.54

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther (2010) 4.54

CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39

Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34

Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem (2001) 4.23

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med (1999) 3.29

Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity (2010) 3.27

OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity (2001) 3.08

Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A (2006) 3.04

Molecular basis of T cell inactivation by CTLA-4. Science (1998) 3.00

Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother (2010) 3.00

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 2.86

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med (1999) 2.77

Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol (1998) 2.74

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73

Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 2.69

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med (1999) 2.61

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood (2009) 2.54

OX40 costimulation turns off Foxp3+ Tregs. Blood (2007) 2.52

Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J Exp Med (2001) 2.49

Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med (1982) 2.42

The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science (1987) 2.35

Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science (2012) 2.26

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA (1986) 2.26

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal (2012) 2.24

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21

Peripheral tolerance of CD8 T lymphocytes. Immunity (2005) 2.21

Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor. EMBO J (1990) 2.21

II. Contribution to the Knowledge of Sarcoma. Ann Surg (1891) 2.21

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med (2006) 2.16

Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol (2001) 2.13

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature (2012) 2.08

Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med (2012) 2.04

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci (2009) 1.96

IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol (2007) 1.92

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine (2009) 1.92

Articles by these authors

Antigen-specific TGF-β-induced regulatory T cells secrete chemokines, regulate T cell trafficking, and suppress ongoing autoimmunity. J Immunol (2011) 1.13

Induction of tolerance in CD8+ T cells to a transgenic autoantigen expressed in the liver does not require cross-presentation. J Immunol (2007) 1.09

CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest (2013) 1.04

Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res (2012) 0.98

Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR. Mol Ther (2009) 0.96

Structures of manganese polysulfides: mass-selected photodissociation and density functional calculations. Dalton Trans (2011) 0.90

Photoelectron spectroscopy and density functional calculations of CuSi(n)- (n = 4-18) clusters. J Chem Phys (2012) 0.88

Identification of HIV-1 inhibitors targeting the nucleocapsid protein. J Med Chem (2012) 0.85

Rapid deep sequencing of patient-derived HIV with ion semiconductor technology. J Virol Methods (2013) 0.85

Identification and characterization of 177 unreported genes associated with liver regeneration. Genomics Proteomics Bioinformatics (2004) 0.81

Mechanical properties and failure mechanisms of graphene under a central load. Chemphyschem (2014) 0.80

CD8+ T cell exhaustion during persistent viral infection is regulated independently of the virus-specific T cell receptor. Immunol Invest (2013) 0.79

HIV-1 determinants of thrombocytopenia at the stage of CD34+ progenitor cell differentiation in vivo lie in the viral envelope gp120 V3 loop region. Virology (2010) 0.75

Rescue of multi-lineage hematopoiesis during HIV-1 infection by human c-mpl gene transfer and reconstitution of CD34+ progenitor cells in vivo. J Stem Cells (2009) 0.75

Large scale of identification of differentially expressed genes in the regenerating rat liver after SISPH. Sci China C Life Sci (2005) 0.75

Erratum: Structural isomerism in gold nanoparticles revealed by X-ray crystallography. Nat Commun (2015) 0.75

Tunable thermal transport and mechanical properties of graphyne heterojunctions. Phys Chem Chem Phys (2016) 0.75